Natus Medical Incorporated Files Response to U.S. International Trade Commission's Investigation

Intends to defend itself against Ceribell's complaint while preserving competition in the industry and improving the quality of patient care

MIDDLETON, Wis., Aug. 26, 2025 /PRNewswire/ -- Natus Medical Incorporated ("Natus" or the "Company"), the trusted solution source by healthcare providers around the globe to screen, diagnose, and treat disorders affecting the brain and neural pathways, today announced that it has filed its response against the complaint filed by CeriBell, Inc. ("Ceribell"), alleging patent infringement. The complaint, which was filed with the U.S. International Trade Commission ("USITC"), alleges violations of section 337 of the Tariff Act of 1930 in the alleged importation into the United States and sale of certain wearable electroencephalogram devices and systems and components thereof that allegedly infringe patents asserted by Ceribell. 

Natus's response follows Ceribell's request, filed on July 7, 2025, to the USITC to investigate its allegations seeking to prevent continued sales of Natus's latest commercialized innovation, BrainWatch, in the U.S. marketplace.

Launched in May of this year, BrainWatch is a point-of-care EEG solution designed to bring real-time seizure detection to hospitals nationwide, providing potentially lifesaving care to Emergency Room ("ER") and/or Intensive Care Unit ("ICU") patients who are at increased risk of seizures. BrainWatch offers a customized and systemic solution for both ER and ICU teams, as it represents the only point-of-care EEG solution that seamlessly integrates neurology workflows through the Company's NeuroWorks system, and opens the channel for patients to receive neurological care immediately following use.

Considering the ease of use enabled by seamless integration into Natus's NeuroWorks Persyst technology—a system that appears in the majority of American hospitals—neurologists should be eager to welcome BrainWatch technology into their hospitals. In turn, this compatibility supports easily translatable studies, which can aid in the process of insurance reimbursement for hospitals and patients alike.  

"Over the course of our over 85-year lineage, Natus has been guided by our mission to support patients' transition into the appropriate care pathways and improve patient outcomes. By working from neurology outward, we have grown to be a trusted and reliable source for EEG product offerings in the market across the U.S. and internationally, and we remain deeply committed to serving the neurology community, including both doctors and patients," said Natus CEO Chris Landon. "We are confident that healthy competition in this market will ensure that patients receive the most innovative, sophisticated technology available to them. Natus will continue to defend itself against Ceribell's allegations with patient and doctor choice as our top priority."

Key highlights from Natus's response, which was filed today with the USITC, include:

• Patent Infringement: Natus denies infringement and that there was any "copying" of Ceribell's product.
• U.S. Production Claims: Natus is proud to have its product rooted in U.S. manufacturing, as BrainWatch is largely produced in Wisconsin where the Company is headquartered. We are confident in our ability to continue to supply the market with the industry's leading and most innovative point-of-care solutions. Ceribell is a Chinese investment firm-backed entrant into the EEG market, whose headband is manufactured in China and Vietnam.

Natus maintains its confidence that the Company's BrainWatch system has the potential to significantly impact patient care and improve clinical and economic outcomes both in the ER and ICU. Natus urges and will continue to argue to the USITC that any restriction on the ability of Natus to sell BrainWatch in the U.S. will prevent access to care that Natus can provide to patients and that Ceribell's arguments create a dangerous precedent for medical technological advancements.

About Natus

Natus is trusted by healthcare providers around the globe as the solution source to screen, diagnose, and treat disorders affecting the brain and neural pathways. The best-in-class Natus solutions, including service, field support and education, enable clinicians to advance their standard of care, improving patient outcomes and quality of life. For more information on Natus, please visit natus.com/neuro.

Media Contact:

Prosek Partners for Natus
Andrew Merrill / Rachel Eccles
[email protected]

SOURCE Natus Medical Incorporated